Artiva Biotherapeutics Announces Pricing of $300 Million Underwritten Offering of Common Stock and Pre-Funded Warrants

Rhea-AI Summary

Artiva Biotherapeutics (Nasdaq: ARTV) priced an underwritten offering expected to raise approximately $300 million of gross proceeds through the sale of 23,871,526 common shares at $11.52 per share and pre-funded warrants for 2,170,138 shares at $11.5199 per share.

The offering is expected to close on or about May 11, 2026, subject to customary closing conditions; proceeds are stated before underwriting discounts, commissions and offering expenses.

Positive

• $300M gross proceeds expected
• Large institutional participation including multiple healthcare investors
• Offering uses an effective Form S-3 shelf registration

Negative

• Issuance of 23.9M common shares and 2.17M pre-funded warrants (share dilution)
• Proceeds reported before underwriting discounts, commissions, and expenses
• Closing subject to customary conditions; not guaranteed by May 11, 2026

News Market Reaction – ARTV

-13.02% 7.4x vol

23 alerts

-13.02% News Effect

+22.1% Peak Tracked

-21.9% Trough Tracked

-$46M Valuation Impact

$309.45M Market Cap

7.4x Rel. Volume

On the day this news was published, ARTV declined 13.02%, reflecting a significant negative market reaction. Argus tracked a peak move of +22.1% during that session. Argus tracked a trough of -21.9% from its starting point during tracking. Our momentum scanner triggered 23 alerts that day, indicating elevated trading interest and price volatility. This price movement removed approximately $46M from the company's valuation, bringing the market cap to $309.45M at that time. Trading volume was exceptionally heavy at 7.4x the daily average, suggesting significant selling pressure.

Data tracked by StockTitan Argus on the day of publication.

Market Context

The stock dropped -13.0% in the session following this news. A negative reaction despite the capital...

Analysis

The stock dropped -13.0% in the session following this news. A negative reaction despite the capital raise fits a pattern where financing-related dilution can outweigh balance sheet strengthening. Previous news, including earnings and leadership changes, often saw positive or modest moves, with only one conference update linked to a -7.2% decline. The new stock and pre‑funded warrant issuance expands the share count, so pressure could persist if demand from long-term holders does not absorb the additional supply or if clinical catalysts lag expectations.

Key Figures

Common shares offered: 23,871,526 shares Offering price: $11.52 per share Pre-funded warrants: 2,170,138 warrants +5 more

8 metrics

Common shares offered 23,871,526 shares Underwritten offering size

Offering price $11.52 per share Price for common stock in offering

Pre-funded warrants 2,170,138 warrants Pre-funded warrants in lieu of common shares

Pre-funded purchase price $11.5199 per warrant Purchase price for each pre-funded warrant

Warrant exercise price $0.0001 per share Exercise price of pre-funded warrants

Gross proceeds $300 million Expected gross proceeds before expenses

Q1 2026 net loss $23.5 million Quarter ended March 31, 2026 (10-Q/8-K)

Cash & investments $86.8 million Balance as of March 31, 2026 (10-Q/8-K)

Historical Context

5 past events · Latest: Apr 08 (Neutral)

Pattern 5 events

Date	Event	Sentiment	24h Move	Catalyst
Apr 08	Conference participation	Neutral	-7.2%	Announcement of participation in the Needham Virtual Healthcare Conference.
Mar 10	Earnings & pipeline	Positive	+17.3%	Full-year 2025 results and positive AlloNK clinical and regulatory updates.
Feb 25	Conference participation	Neutral	+0.2%	Participation in TD Cowen healthcare conference with investor meetings.
Feb 24	CFO appointment	Positive	+4.6%	Hiring of new CFO with significant industry experience and RSU grant.
Feb 19	Board appointment	Positive	+9.2%	Addition of experienced biopharma executive to the board of directors.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Pattern Detected

Recent news has generally seen positive or modest reactions, with a larger selloff only on a conference-participation update.

Recent Company History

Over recent months, Artiva’s news flow has focused on corporate positioning and clinical progress. Management and board appointments in February 2026 were followed by price gains of 4.58% and 9.16%. The full‑year 2025 financial and clinical update on AlloNK in March 2026 saw a 17.27% rise, while routine conference participation headlines produced only small or negative moves. Against this backdrop, today’s underwritten equity and pre‑funded warrant offering adds a capital-raising step to an already active clinical and corporate agenda.

Key Terms

underwritten offering, pre-funded warrants, shelf registration statement, form s-3, +2 more

6 terms

underwritten offering financial

"today announced the pricing of an underwritten offering of 23,871,526 shares"

An underwritten offering is when a bank or group of banks agrees to buy all of a company's new shares or bonds and then resell them to outside investors, guaranteeing the company will raise a specific amount of money. It matters to investors because it adds certainty that the funding will close while increasing the number of shares or debt in the market, which can lower the price per share and change each existing owner's ownership percentage—think of a wholesaler buying an entire shipment from a maker before it reaches stores.

pre-funded warrants financial

"in lieu of shares of common stock to certain investors, pre-funded warrants to purchase"

Pre-funded warrants are financial instruments that give investors the right to purchase a company's stock at a set price, but with most or all of the purchase price paid upfront. They function like a coupon or gift card for stock, allowing investors to buy shares later at a fixed price, which can be beneficial if they want to avoid future price increases. This makes them important for investors seeking flexibility and certainty in their investment plans.

shelf registration statement regulatory

"offered by Artiva pursuant to a shelf registration statement on Form S-3, including a base"

A shelf registration statement is a document a company files with regulators that allows it to sell shares or bonds quickly when it’s a good time to raise money. It’s like having a pre-approved plan ready so the company can act fast without going through lengthy paperwork each time they want to sell, making fundraising more flexible.

form s-3 regulatory

"pursuant to a shelf registration statement on Form S-3, including a base prospectus"

Form S-3 is a legal document companies use to register their stock sales with the government, making it easier and faster for them to raise money by selling shares to investors. It’s like having a pre-approved shopping list that lets a company quickly sell new shares when they need funds, without going through a lengthy approval process each time.

base prospectus regulatory

"registration statement on Form S-3, including a base prospectus, filed with the"

A base prospectus is a detailed document that provides essential information about a financial offering, such as a bond or share issue. It acts like a comprehensive guide for investors, explaining what the investment involves, the risks involved, and how the process works. This helps investors make informed decisions before committing their money.

prospectus supplement regulatory

"A prospectus supplement and accompanying prospectus relating to the offering will be filed"

A prospectus supplement is an additional document provided alongside a company's main offering details, offering updated or extra information about a specific financial product being sold. It helps investors understand the latest terms, risks, and details of the investment, similar to how an update or revision clarifies or expands on original instructions, ensuring they have current and complete information before making a decision.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

SAN DIEGO, May 08, 2026 (GLOBE NEWSWIRE) -- Artiva Biotherapeutics, Inc. (Nasdaq: ARTV) (Artiva), a clinical-stage biotechnology company whose mission is to develop effective, safe and accessible cell therapies for patients with debilitating autoimmune diseases, today announced the pricing of an underwritten offering of 23,871,526 shares of its common stock at a price of $11.52 per share and, in lieu of shares of common stock to certain investors, pre-funded warrants to purchase 2,170,138 shares of common stock at a purchase price of $11.5199 per share, which equals the offering price per share of the common stock less the $0.0001 exercise price per share of each pre-funded warrant. All the shares of common stock and pre-funded warrants in the offering are being sold by Artiva.

The gross proceeds to Artiva from the offering are expected to be approximately $300 million, before deducting underwriting discounts and commissions and other offering expenses payable by Artiva. The offering is expected to close on or about May 11, 2026, subject to the satisfaction of customary closing conditions.

The offering included participation from Caligan Partners, Venrock Healthcare Capital Partners, Adage Capital Partners, RA Capital Management, Viking Global Management, Samsara BioCapital, EcoR1 Capital, Blackstone Multi-Asset Investing, GC Corporation, GC Cell, RTW Investments, Blue Owl Healthcare Opportunities and a Large Mutual Fund.

Jefferies, TD Cowen and Cantor are acting as joint book-running managers for the offering. Wedbush PacGrow and Needham & Company are acting as co-lead managers for the offering.

The shares of common stock and pre-funded warrants described above are being offered by Artiva pursuant to a shelf registration statement on Form S-3, including a base prospectus, filed with the Securities and Exchange Commission (the SEC) that was declared effective on August 15, 2025. A prospectus supplement and accompanying prospectus relating to the offering will be filed with the SEC and will be available for free through the SEC’s website at www.sec.gov. Copies of the prospectus supplement and the accompanying prospectus relating to the offering, when available, may be obtained from: Jefferies LLC, Attention: Equity Syndicate Prospectus Department, 520 Madison Avenue, New York, New York 10022, or by telephone at (877) 821-7388, or by emailing prospectus_department@jefferies.com; TD Securities (USA) LLC, c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, NY 11717, or by email at TDManualrequest@broadridge.com; or from Cantor Fitzgerald & Co., Attention: Capital Markets, 110 East 59^th Street, 6^th Floor, New York, NY 10022 or by email at prospectus@cantor.com.

This press release shall not constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

About Artiva Biotherapeutics

Artiva is a clinical-stage biotechnology company whose mission is to develop effective, safe and accessible cell therapies for patients with debilitating autoimmune diseases. Artiva’s lead program, AlloNK^® (also known as AB-101), is an allogeneic, off-the-shelf, non-genetically modified, cryopreserved NK cell therapy candidate designed to enhance the antibody-dependent cellular cytotoxicity effect of monoclonal antibodies to drive B-cell depletion. AlloNK is currently being evaluated in three ongoing clinical trials for the treatment of B-cell driven autoimmune diseases, including a company-sponsored basket trial across autoimmune diseases that includes rheumatoid arthritis and Sjögren disease and an investigator-initiated basket trial in B-cell driven autoimmune diseases. Artiva plans to initiate a Phase 3 registrational trial evaluating AlloNK in refractory RA in 2026. Artiva was founded in 2019 as a spin out of GC Cell, formerly GC Lab Cell Corporation, a leading healthcare company in the Republic of Korea, pursuant to a strategic partnership granting Artiva exclusive worldwide rights (excluding Asia, Australia and New Zealand) to GC Cell’s NK cell manufacturing technology and programs.

Artiva is headquartered in San Diego, California.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. In some cases, you can identify forward-looking statements by terminology such as “aim,” “anticipate,” “assume,” “believe,” “contemplate,” “continue,” “could,” “design,” “due,” “estimate,” “expect,” “goal,” “intend,” “may,” “objective,” “plan,” “positioned,” “potential,” “predict,” “seek,” “should,” “suggest,” “target,” “on track,” “will,” “would” and other similar expressions that are predictions of or indicate future events and future trends, or the negative of these terms or other comparable terminology. All statements other than statements of historical facts contained in this press release are forward-looking statements. These forward-looking statements include, but are not limited to, statements about the completion and timing of the offering and the anticipated gross proceeds from the offering. Forward-looking statements are not guarantees of future performance and are subject to risks and uncertainties that could cause actual results and events to differ materially from those anticipated, including, but not limited to, risks and uncertainties related to, among other things, market conditions and the satisfaction of customary closing conditions related to the offering. These and other risks are described in greater detail under the section titled “Risk Factors” contained in Artiva’s filings with the SEC, including Artiva’s Quarterly Report on Form 10-Q for the quarter ended March 31, 2026, filed with the SEC on May 6, 2026. Any forward-looking statements that Artiva makes in this press release are made pursuant to the Private Securities Litigation Reform Act of 1995, as amended, and speak only as of the date of this press release. Except as required by law, Artiva undertakes no obligation to publicly update any forward-looking statements, whether as a result of new information, future events or otherwise.

Contacts

Investors
Noopur Batsha Liffick, MPH
NBL LifeSci Advisory LLC
ir@artivabio.com

Media
Jessica Yingling, Ph.D.
Little Dog Communications Inc.
jessica@litldog.com

FAQ

How much is Artiva (ARTV) raising in the May 2026 offering?

Approximately $300 million in gross proceeds. According to the company, the amount is stated before underwriting discounts, commissions and other offering expenses payable by Artiva.

What securities did Artiva (ARTV) offer in the May 8, 2026 placement?

Artiva offered common stock and pre-funded warrants. According to the company, 23,871,526 common shares and pre-funded warrants to purchase 2,170,138 shares were included in the offering.

What price per share did Artiva (ARTV) set for the offering?

Common shares priced at $11.52 per share and pre-funded warrants at $11.5199. According to the company, the warrant price equals the common price minus $0.0001 exercise price.

When is the Artiva (ARTV) offering expected to close and what conditions apply?

The offering is expected to close on or about May 11, 2026. According to the company, close remains subject to customary closing conditions and is not guaranteed until completed.

Who led Artiva's (ARTV) underwritten offering and where is the prospectus available?

Jefferies, TD Cowen and Cantor acted as joint book-running managers. According to the company, the prospectus supplement will be filed with the SEC and available at www.sec.gov.